Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Berkshire Hathaway Inc Class B (BRK.B) vs Cassava Sciences Inc (FLNA) Price & Performance

Berkshire Hathaway Inc Class BTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

Berkshire Hathaway Inc Class B vs Cassava Sciences Inc — how do they compare? Berkshire Hathaway Inc Class B trades at $515.67, while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: Berkshire Hathaway Inc Class B is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

BRK.BFLNA
Sector
FinancialsHealth
52-Week High
$529.65$4.64
52-Week Low
$465.39$0.87
Market Cap
$47.75M
Enterprise Value
-$34.93M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Berkshire Hathaway Inc Class B

BRK.B trades at $529.65, up 1.73% today, with a bullish technical signal from moving averages and oscillators. The stock is near its pivot point of $530, with support at $522 and resistance at $536. Analyst consensus is positive, with 57% of 7 analysts rating it a Buy and none recommending Sell, indicating strong institutional confidence.

The outlook remains favorable given the bullish technicals and analyst support, though overbought RSI readings suggest near-term caution. Key risks include market volatility and macroeconomic pressures, but the stock's strong fundamentals and institutional backing provide a solid foundation for potential growth.

Cassava Sciences Inc

FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.

The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Berkshire Hathaway Inc Class B

Berkshire Hathaway is a holding company with diverse subsidiaries, primarily in insurance through Geico and its reinsurance groups. It reinvests profits into various industries, owning Burlington Northern Santa Fe (railroad), Berkshire Hathaway Energy, and major manufacturing, service, and retail businesses like Precision Castparts and Lubrizol. The company operates in a highly decentralized manner.

Read more on BRK.B

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA